Earnings summaries and quarterly performance for Penumbra.
Executive leadership at Penumbra.
Board of directors at Penumbra.
Research analysts who have asked questions during Penumbra earnings calls.
Richard Newitter
Truist Securities
4 questions for PEN
Also covers: AXNX, DXCM, GKOS +18 more
Robert Marcus
JPMorgan Chase & Co.
4 questions for PEN
Also covers: ABT, BAX, BDX +21 more
Macauley Kilbane
William Blair & Company
3 questions for PEN
Also covers: CBLL, CVRX, GKOS +4 more
Michael Sarcone
Jefferies
3 questions for PEN
Also covers: ALC, AXGN, CTSO +11 more
Pito Chickering
Deutsche Bank
3 questions for PEN
Also covers: ACHC, AHCO, AVAH +18 more
Ryan Zimmerman
BTIG
3 questions for PEN
Also covers: ALC, GEHC, GKOS +23 more
Joanne Wuensch
Citigroup Inc.
2 questions for PEN
Also covers: ABT, BAX, BDX +18 more
Lei Huang
Wells Fargo
2 questions for PEN
Also covers: NVCR, RXST, SOLV
Michael Kratky
Leerink Partners
2 questions for PEN
Also covers: AXGN, BBNX, DXCM +6 more
Samantha Kurtz
Piper Sandler Companies
2 questions for PEN
Also covers: SYK
Travis Steed
Bank of America
2 questions for PEN
Also covers: ABT, AXNX, BAX +19 more
William Plovanic
Canaccord Genuity
2 questions for PEN
Also covers: ATRC, CBLL, CVRX +9 more
Bill Plovanic
Canaccord Genuity
1 question for PEN
Also covers: AORT, CBLL, DXCM +6 more
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for PEN
Also covers: ALGN, CBLL, CVRX +16 more
Chris Pasquale
Nephron Research LLC
1 question for PEN
Also covers: ALC, AXGN, BSX +7 more
Christopher Pasquale
Nephron Research
1 question for PEN
Also covers: ALC, AXGN, BSX +12 more
David Rescott
Baird
1 question for PEN
Also covers: HAE, INSP, IRTC +7 more
Kallum Titchmarsh
Morgan Stanley
1 question for PEN
Also covers: ATEC, AXNX, EMBC +5 more
Larry Biegelsen
Wells Fargo & Company
1 question for PEN
Also covers: ABT, ALC, AXNX +24 more
Lawrence Biegelsen
Wells Fargo
1 question for PEN
Also covers: ABT, ALC, BAX +16 more
Mathew Blackman
Stifel
1 question for PEN
Also covers: AHCO, ATEC, BBNX +7 more
Matthew O'Brien
Piper Sandler & Co.
1 question for PEN
Also covers: APYX, ATEC, ATRC +18 more
Michael Matson
Needham & Company
1 question for PEN
Also covers: AORT, ATRC, CNMD +22 more
Samantha Munoz
Piper Sandler Companies
1 question for PEN
Also covers: ATEC, CVRX, TELA +1 more
Shagun Singh Chadha
RBC Capital Markets
1 question for PEN
Also covers: AXNX, DXCM, GMED +11 more
Recent press releases and 8-K filings for PEN.
Penumbra Discusses Strong Q3 Performance, New Products, and Clinical Trial Results
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong Q3 performance in its MO and access business, driven by the launch of Ruby XL and the expansion of its sales force.
- The company highlighted a significant growth opportunity in MMA embolization on the neuro side, with a potential $1 billion opportunity for this new procedure.
- Results from the STORM-PE trial demonstrated that mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism treatment, showing high safety and fast procedure times (25-minute device time, 56-minute procedure time), which is expected to drive increased market penetration.
- Penumbra introduced 3.0, an updated product with both software and hardware changes, offering faster operation and less blood loss compared to its predecessor.
- The FDA review process for the Thunderbolt product is described as thorough but routine, with the company addressing clarifying questions.
Dec 3, 2025, 1:00 PM
Penumbra Highlights Strong Q3 Performance, New Product Launches, and Positive Clinical Data
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong performance in its MO and access business in Q3, driven by a new sales force and the successful launch of Ruby XL, a large vessel coil for peripheral vascular embolization.
- The company is experiencing significant growth in neuro embolization, particularly from the new MMA embolization procedure, which is seen as a potential $1 billion opportunity.
- The STORM-PE study demonstrated that Penumbra's mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism, showing extraordinary safety, significant RV/LV ratio reduction, and rapid procedure times. This data is influencing hospital protocols and expanding market penetration.
- Penumbra introduced 3.0, an enhanced thrombectomy product that offers faster operation and reduced blood loss, and is currently navigating the FDA review process for its Thunderbolt product, which is expected to have a higher average selling price.
Dec 3, 2025, 1:00 PM
Penumbra Discusses Q3 Performance, Product Innovations, and Market Opportunities
PEN
Product Launch
Revenue Acceleration/Inflection
New Projects/Investments
- Penumbra reported strong Q3 performance in its MO and access business, driven by the launch of Ruby XL and an expanded sales force.
- The company anticipates significant growth in its embolization franchise, particularly from MMA embolization, which is estimated to be a $1 billion opportunity.
- Positive results from the STORM-PE trial demonstrated that mechanical thrombectomy with CAVT is superior to anticoagulation for pulmonary embolism, with high safety and fast procedure times (25-minute device times, 56-minute procedure times). This data is expected to accelerate market penetration and change hospital protocols.
- Penumbra launched its 3.0 product, an upgrade to 2.0, which offers faster operation and reduced blood loss due to both software and hardware changes.
- The new neuro product, Thunderbolt, is currently under FDA review, with the company addressing clarifying questions, and is expected to have a higher average selling price (ASP) upon clearance.
Dec 3, 2025, 1:00 PM
Penumbra Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance
PEN
Earnings
Guidance Update
Product Launch
- Penumbra generated total revenue of $354.7 million in Q3 2025, representing 17.8% year-over-year growth on a reported basis, and subsequently raised its full-year 2025 revenue guidance to $1,375 million-$1,380 million.
- The company achieved a gross margin of 67.8% in Q3 2025, an expansion of 130 basis points over the prior year, and reported operating income of $48.8 million, or 13.8% of revenue.
- U.S. revenue increased 21.5% year-over-year, driven by 18.5% growth in thrombectomy sales and 29.2% growth in embolization and access, with the latter benefiting from a new dedicated sales team and the RubyXL product launch.
- Penumbra received FDA clearance for Lightning Bolt 16 and Lightning Flash 3.0 and presented landmark results from the Storm PE trial, which demonstrated the superiority of CABT in reducing right heart strain with a comparable safety profile.
Nov 5, 2025, 9:30 PM
Penumbra, Inc. Reports Strong Third Quarter 2025 Financial Results and Raises Full-Year Revenue Guidance
PEN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Penumbra, Inc. reported Q3 2025 revenue of $354.7 million, an increase of 17.8% compared to Q3 2024.
- Total U.S. revenue for Q3 2025 was $275.0 million, representing a 21.5% increase year-over-year, with U.S. Thrombectomy revenue growing 18.5% to $192.0 million.
- The company achieved net income of $45.9 million (12.9% margin) and adjusted EBITDA of $66.7 million (18.8% margin) in Q3 2025.
- Penumbra has increased its full-year 2025 revenue guidance to a range of $1.375 billion to $1.380 billion, which represents 15% to 16% growth over 2024 revenue.
Nov 5, 2025, 9:15 PM
Penumbra Reports Strong Third Quarter 2025 Financial Results
PEN
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Penumbra, Inc. reported revenue of $354.7 million for the third quarter ended September 30, 2025, marking a 17.8% increase compared to the third quarter of 2024.
- Total U.S. revenue for Q3 2025 was $275.0 million, an increase of 21.5% over the same period last year, with U.S. Thrombectomy revenue growing 18.5% to $192.0 million.
- The company achieved net income of $45.9 million and adjusted EBITDA of $66.7 million in the third quarter of 2025.
- Penumbra increased its full-year 2025 total revenue guidance to a range of $1.375 billion to $1.380 billion, which represents 15% to 16% growth over 2024 revenue.
Nov 5, 2025, 9:05 PM
Penumbra Announces Positive STORM-PE Trial Results for CAVT in Pulmonary Embolism Treatment
PEN
- Penumbra announced on November 3, 2025, additional positive results from its STORM-PE randomized controlled trial (RCT) for the treatment of acute intermediate-high risk pulmonary embolism (PE).
- The trial demonstrated that computer assisted vacuum thrombectomy (CAVT™) with anticoagulation achieved significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone.
- Patients treated with CAVT plus anticoagulation showed a 2.7 times larger reduction in refined modified Miller score and a 2.2 times greater likelihood of progressing towards recovery of functional status.
- The safety rates through 90 days were comparable, with no device-related mortality and no difference in symptomatic PE-recurrence, confirming CAVT's safety profile.
- These findings were presented at the VIVA 2025 Conference and published in Circulation.
Nov 3, 2025, 8:00 PM
Penumbra Announces Positive Results from Landmark STORM-PE Trial
PEN
New Projects/Investments
- Penumbra, Inc. announced that its landmark STORM-PE randomized controlled trial found computer assisted vacuum thrombectomy (CAVT™) with anticoagulation superior to anticoagulation alone for reducing right heart strain in patients with acute intermediate-high risk pulmonary embolism (PE).
- The trial demonstrated that CAVT patients achieved a greater reduction in right-to-left ventricular (RV/LV) diameter ratio within 48 hours (mean reduction 0.52 vs. 0.24) and nearly 80% had a positive treatment effect, indicating rapid hemodynamic recovery.
- Importantly, the rate of major adverse events within 7 days was comparable between the CAVT and anticoagulation-only groups (4.3% vs. 7.5%), with CAVT achieving superior efficacy without increased complications.
- These results provide the first prospective, level 1 evidence of CAVT's superiority, which is expected to play a critical role in advancing PE care and supporting its inclusion in future treatment guidelines.
Oct 27, 2025, 1:00 PM
Penumbra's CABT Device Trial Demonstrates Superiority in Pulmonary Embolism Treatment
PEN
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- The first randomized trial in over a decade evaluating endovascular therapy versus anticoagulation for acute pulmonary embolism (PE) demonstrated the superiority of Penumbra's CABT procedure (Lightning Flash System) over anticoagulation alone in treating intermediate high-risk PE patients.
- The CABT procedure achieved a statistically superior reduction in the RV to LV ratio, the primary efficacy endpoint, compared to anticoagulation alone, indicating a faster and more uniform reduction of strain on the heart.
- The trial reported a comparable safety profile between the CABT group (two major adverse events) and the anticoagulation group (four major adverse events), with no statistical significance.
- This foundational trial is expected to influence future treatment guidelines and expand patient access, as intermediate high-risk PE affects an estimated 15% to 25% of all PE patients in the U.S..
Oct 26, 2025, 11:00 PM
Penumbra's Lightning Flash System Trial Shows Superiority for Pulmonary Embolism
PEN
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- A randomized clinical trial for Penumbra's (PEN) Lightning Flash System demonstrated significantly superior reduction in right ventricle to left ventricle (RV to LV) ratio for acute pulmonary embolism (PE) patients compared to anticoagulation alone.
- The trial, the first of its kind in over a decade for mechanical thrombectomy versus anticoagulation, showed that 78% of patients treated with the Lightning Flash System achieved a therapeutic effect (0.2 reduction in RV to LV ratio) versus 52% with anticoagulation alone.
- The study reported an impressive safety profile for the device, even with operators having limited prior experience.
- This foundational trial is expected to be a "game changer" for intermediate high-risk PE treatment, potentially expanding the market for mechanical thrombectomy to tens to hundreds of thousands of patients annually in the US, and is anticipated to influence future medical guidelines.
Oct 26, 2025, 11:00 PM
Quarterly earnings call transcripts for Penumbra.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more